Faldaprevir

Faldaprevir was an experimental drug for the treatment of hepatitis C (HCV). It was being developed by Boehringer-Ingelheim and reached Phase III clinical trials in 2011.[1] Boehringer announced in 2014 that it would not pursue approval of the drug any more because of better HCV treatments having become available.[2]

Faldaprevir
Clinical data
Other namesBI 201335
Routes of
administration
By mouth
ATC code
Legal status
Legal status
  • Abandoned
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC40H49BrN6O9S
Molar mass869.83 g·mol−1
3D model (JSmol)

Mechanism of action

Faldaprevir is a hepatitis C virus protease inhibitor.

Studies

Faldaprevir was tested in combination regimens with pegylated interferon and ribavirin, and in interferon-free regimens with other direct-acting antiviral agents including deleobuvir.

Data from the SOUND-C2 study, presented at the 2012 AASLD Liver Meeting, showed that a triple combination of faldaprevir, deleobuvir, and ribavirin performed well in HCV genotype 1b patients.[3] Efficacy fell below 50%, however, for dual regimens without ribavirin and for genotype 1a patients.

References

  1. Clinical trial number NCT01343888 for "Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)" at ClinicalTrials.gov
  2. "Hepatitis C: Aus für Boehringers Faldaprevir". www.pharmazeutische-zeitung.de.
  3. Interferon-free hepatitis C treatment with faldaprevir proves safe and effective in people with cirrhosis. Alcorn, K. Aidsmap.com. 20 November 2012.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.